CINECA IRIS Institutional Research Information System

DEL RE, MARZIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.744
AS - Asia 6.184
EU - Europa 4.851
SA - Sud America 1.148
Continente sconosciuto - Info sul continente non disponibili 554
AF - Africa 374
OC - Oceania 24
AN - Antartide 1
Totale 25.880
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.406
SG - Singapore 2.118
IT - Italia 1.955
CN - Cina 1.508
HK - Hong Kong 1.067
BR - Brasile 926
SE - Svezia 635
VN - Vietnam 595
GB - Regno Unito 410
DE - Germania 407
BG - Bulgaria 302
FR - Francia 267
CA - Canada 207
FI - Finlandia 174
IN - India 163
CI - Costa d'Avorio 157
RU - Federazione Russa 157
JP - Giappone 148
TR - Turchia 133
AT - Austria 132
NL - Olanda 110
AR - Argentina 82
BD - Bangladesh 81
PL - Polonia 68
KR - Corea 63
SN - Senegal 61
MX - Messico 56
IQ - Iraq 50
ZA - Sudafrica 47
ES - Italia 46
ID - Indonesia 33
PK - Pakistan 32
UA - Ucraina 32
BE - Belgio 31
SA - Arabia Saudita 31
VE - Venezuela 31
EC - Ecuador 28
MA - Marocco 24
NG - Nigeria 23
UZ - Uzbekistan 23
CO - Colombia 21
LT - Lituania 19
AU - Australia 18
CH - Svizzera 17
CR - Costa Rica 17
KE - Kenya 16
PH - Filippine 15
UY - Uruguay 15
CL - Cile 13
CZ - Repubblica Ceca 13
PY - Paraguay 13
RO - Romania 12
TW - Taiwan 12
JM - Giamaica 11
IL - Israele 10
JO - Giordania 10
MY - Malesia 10
PE - Perù 10
EU - Europa 9
KZ - Kazakistan 9
NP - Nepal 9
AE - Emirati Arabi Uniti 8
BO - Bolivia 8
IE - Irlanda 8
TN - Tunisia 8
TT - Trinidad e Tobago 8
AL - Albania 7
AZ - Azerbaigian 7
DO - Repubblica Dominicana 7
LB - Libano 7
PA - Panama 7
EG - Egitto 6
LV - Lettonia 6
SV - El Salvador 6
TH - Thailandia 6
DK - Danimarca 5
ET - Etiopia 5
GR - Grecia 5
GT - Guatemala 5
NO - Norvegia 5
PT - Portogallo 5
BJ - Benin 4
GH - Ghana 4
HR - Croazia 4
HU - Ungheria 4
IR - Iran 4
LK - Sri Lanka 4
NZ - Nuova Zelanda 4
AM - Armenia 3
AO - Angola 3
BB - Barbados 3
BF - Burkina Faso 3
BH - Bahrain 3
BY - Bielorussia 3
DZ - Algeria 3
GE - Georgia 3
HN - Honduras 3
KW - Kuwait 3
LU - Lussemburgo 3
NI - Nicaragua 3
Totale 25.291
Salva come PNG Salva come JPEG
Città #
Ashburn 1.441
Singapore 1.102
Hong Kong 1.049
Fairfield 906
Woodbridge 878
Dallas 872
Santa Clara 807
San Jose 690
Houston 623
Ann Arbor 584
Chandler 548
Serra 434
Shanghai 421
Seattle 401
Wilmington 319
New York 311
Sofia 300
Beijing 286
Boardman 266
Council Bluffs 266
Cambridge 264
London 244
Los Angeles 237
Florence 183
Pisa 179
Princeton 177
Ho Chi Minh City 165
Abidjan 157
Lawrence 148
Lauterbourg 141
Milan 125
Tokyo 122
Medford 121
Vienna 119
Ottawa 106
Hanoi 103
Munich 97
Frankfurt am Main 89
Hefei 88
São Paulo 88
Buffalo 80
Rome 70
Redondo Beach 69
Istanbul 68
Chicago 66
San Diego 66
Dearborn 62
Warsaw 62
Dakar 61
Des Moines 60
Nanjing 60
Helsinki 58
Dong Ket 52
Seoul 52
Turku 52
Turin 49
Rio de Janeiro 43
Phoenix 41
Bremen 39
Ogden 39
Nuremberg 37
Boulder 33
Cascina 33
Toronto 32
Orem 30
Montreal 29
Izmir 28
Redwood City 28
Da Nang 27
Brussels 24
Fuzhou 24
Kunming 24
Düsseldorf 23
Lagos 23
San Francisco 23
Paris 22
Washington 22
Denver 21
Tashkent 21
Brasília 20
Chennai 20
Stockholm 20
Brooklyn 19
Guangzhou 19
Livorno 19
Nanchang 19
Naples 19
New Delhi 19
Baghdad 18
Changsha 18
Columbus 18
Mumbai 18
Belo Horizonte 17
Johannesburg 17
Amsterdam 16
Hyderabad 16
Jacksonville 16
Mexico City 16
Quanzhou 16
Bologna 15
Totale 17.485
Salva come PNG Salva come JPEG
Nome #
Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer 452
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC 331
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. 305
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia 252
Comparison of digital PCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancer 222
Effects of Amiodarone, Thyroid Hormones and CYP2C9 and VKORC1 Polymorphisms on Warfarin Metabolism: A Review of the Literature. 214
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life 213
Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC 211
The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response 207
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients 207
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA 205
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients 202
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer 201
EGFR signaling pathway as therapeutic target in human cancers 201
The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer 198
Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer 196
Methods: For studying pharmacogenetic profiles of combination chemotherapeutic drugs 195
IDH1 mutation is detectable in plasma cell-free DNA and is associated with survival outcome in glioma patients 194
AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer 193
Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment 191
Gene-network analysis predicts clinical response to immunotherapy in patients affected by NSCLC 186
Clinical utility of Next Generation Sequencing of plasma cell-free DNA for the molecular profiling of patients with NSCLC at diagnosis and disease progression 186
Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity 186
Droplet digital PCR represents a new sensitive method for detecting B-RAFV600E mutation at diagnosis and during the follow-up of patients affected by hairy cell leukemia 186
Pharmacokinetic Markers of 5-Fluorouracil Toxicity in Clinical Trials and Real World 186
ANKRd44 gene silencing: A putative role in trastuzumab resistance in HER2-like breast cancer 185
Synergistic interaction between PPAR ligands and salbutamol on human bronchial smooth muscle cell proliferation. 184
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer 182
Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro 181
Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy 181
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment 180
Diagnosis and treatment monitoring in breast cancer: how liquid biopsy can support patient management 180
Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. 178
Clinical pharmacology of intravitreal anti-VEGF drugs 178
The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report 177
Comparative evaluation of molecular methods for the quantitative measure of torquetenovirus viremia, the new surrogate marker of immune competence 177
Application of a pharmacokinetic/pharmacogenetic approach to assess the nicotine metabolic profile of smokers in the real-life setting 177
Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines 175
Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors 174
Prediction of fluoropyrimidine toxicities by screening DPYD genetic variants. 174
Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment 174
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials 173
Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide 172
The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients 171
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases 170
eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: Data from a randomized clinical trial 170
Implications of KRAS mutations in acquired resistance to treatment in NSCLC 170
Pharmacogenetics and metabolism from science to implementation in clinical practice: the example of dihydropyrimidine dehydrogenase. 169
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial 168
Comparison of Real-Time PCR and Droplet Digital PCR for the Determination of JAK2V617F Mutation in Ph'-Negative Myeloproliferative Neoplasms 167
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel 165
Pharmacogenetics of androgen signaling in prostate cancer: focus on castration resistance and predictive biomarkers of response to treatment 162
Gemcitabine plus nab-paclitaxel induces PD-L1 mRNA expression in plasma-derived microvesicles in pancreatic cancer 162
Unusual gastrointestinal and cutaneous toxicities by bleomycin, etoposide, and cisplatin: A case report with pharmacogenetic analysis to personalize treatment 160
Author's reply. 159
Pathophysiology and pharmacological targets of VEGF in diabetic macular edema 159
EGFR-TKIs in non-small-cell lung cancer: Focus on clinical pharmacology and mechanisms of resistance 159
PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients 158
Pharmacogenetics of anti-estrogen treatment of breast cancer 157
Pharmacogenetic foundations of therapeutic efficacy and adverse events of statins 157
From the beginning to resistance: study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 157
Prevention of fluoropyrimidine toxicity: do we still have to try our patient's luck? 154
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA 154
Uncommon dihydropyrimidine dehydrogenase mutations and toxicity by fluoropyrimidines: A lethal case with a new variant 154
Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring 154
Genome Wide Association Studies (GWAS) 152
Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer 151
Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight 150
Liquid biopsies from pleural effusions and plasma from patients with malignant pleural mesothelioma: A feasibility study 150
Gene network Analysis Defines a Subgroup of Small Cell Lung Cancer patients With Short Survival 149
Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer 149
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC 148
Results of a comprehensive pharmacogenetic analysis of dihydropyrimidine dehydrogenase in patients treated with fluoropyrimidines and patterns of polymorphisms partially related to treatment tolerability. 147
Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy 147
Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel? 147
Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy 144
null 142
Radiomics and liquid biopsy in oncology: the holons of systems medicine 141
Genetic variation: effect on prostate cancer 140
Recent advances in epigenomics in NSCLC: Real-time detection and therapeutic implications 140
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 140
Recommendations for using molecular assays on liquid biopsy: the first document provided by intersociety Group AIOM, SIF, SIAPEC-IAP, SIBioC 139
Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors 139
The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide 139
Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer 139
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib 138
KRAS mutations as potential mechanism of crizotinib acquired resistance: a study on circulating tumor DNA 137
Pharmacodynamics, clinical findings and approval status of current and emerging tyrosine-kinase inhibitors for pancreatic neuroendocrine tumors 134
Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients 134
Predicting Fluoropyrimidine-Related Toxicity: Turning Wish to Will, The Pamm-Eortc Position 133
Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA 133
CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients 132
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 131
Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer 131
Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine? 131
Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680–7 129
Erratum: Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers 129
Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells 128
Clinical and genetic characterization of dihydropyrimidine dehydrogenase (DPD) deficiency in fluoropyrimidine-treated patients carrying the DPYD*2A allele 127
Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors 127
Totale 17.145
Salva come PNG Salva come JPEG
Categoria #
all - tutte 85.105
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 85.105
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.496 0 46 22 36 237 269 95 74 100 96 93 428
2022/20232.415 299 323 170 170 193 287 33 156 499 25 230 30
2023/20241.704 99 112 263 81 171 327 96 73 40 85 142 215
2024/20255.838 94 205 69 256 579 649 466 333 630 732 645 1.180
2025/20267.315 498 918 907 953 707 514 1.035 334 396 572 314 167
2026/2027672 223 449 0 0 0 0 0 0 0 0 0 0
Totale 25.880